Fusion to acquire radiologand therapy for prostate cancer
An investigational new drug application for an ongoing Phase II…
An investigational new drug application for an ongoing Phase II trial of an alpha-emitting radiopharmaceutical will be acquired by Fusion Pharmaceuticals.